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Abstract
Mesenchymal stem cells have been used for cardiovascular regenerative therapy for decades. These cells have been
established as one of the potential therapeutic agents, following several tests in animal models and clinical trials. In
the process, various sources of mesenchymal stem cells have been identified which help in cardiac regeneration by
either revitalizing the cardiac stem cells or revascularizing the arteries and veins of the heart. Although mesenchymal
cell therapy has achieved considerable admiration, some challenges still remain that need to be overcome in order to
establish it as a successful technique. This in-depth review is an attempt to summarize the major sources of
mesenchymal stem cells involved in myocardial regeneration, the significant mechanisms involved in the process
with a focus on studies (human and animal) conducted in the last 6 years and the challenges that remain to be
addressed.
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Background
Stem cells are capable of differentiating into cells of the
same type, which in turn give rise to other kinds of cells
[1]. Stem cells can be classified on the basis of their origin
and potential to differentiate. Based on origin, these cells
are of two types: embryonic stem cells (ESCs) and non-
ESCs. The non-ESCs are present in two forms: haemato-
poietic stem cells (HSCs) that differentiate into different
blood cells and are CD34+; and the less differentiated
mesenchymal stem cells (MSCs). Under the second
classification system, stem cells can be categorized as
totipotent, pluripotent and multipotent, based on their
potential to differentiate into different cell types. All
stem cells have three common features, namely bound-
less self-renewal capacity, potential for asymmetric divi-
sions and an irreversible differentiation process [2].
Cardiovascular diseases account for the highest mortality
in the western countries of the world [3]. Unlike lower
vertebrates like zebrafish [4], adult mammals do not possess
the capacity for natural heart regeneration throughout their
lifetime [5] and hence several therapeutic measures have
been investigated for myocardial regeneration and repair.
Out of these numerous approaches, the first clinical trials
about a decade ago bolstered stem cell therapy as one of
the potential strategies utilized in the cure of these disor-
ders. The current research in the field of cardiac regenera-
tive medicine thus attempts to stimulate the endogenous
regenerative mechanisms via cell therapy for conditions
such as myocardial infarction (MI). This is achieved by
intermingling of two components: a cardiomyocyte source
as the target for regeneration; and a non-myocardial tissue
acting as a source for regeneration in an effective cardiac
environment [5].
This review focuses on summarizing all studies con-
cerning MSCs in terms of in-vivo and clinical observa-
tions in the last 6 years (2010–2015), following a critical
evaluation of its cardiomyogenic potential as well as the
clinical trials.
Main text
Importance of the MSC niche for cardiac regeneration
The Niche hypothesis [6] proposes the existence of an
optimal microenvironment for stem cells. This concept
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has been pledged to explain the hierarchy of stem cells,
with different degrees of differentiation capacity [2].
In 2011, Vunjak-Novakovic and Scadden [7] categorized
the cellular and acellular components into key factors
such as regulatory molecules (cytokines, O2, nutrients),
extracellular matrix (ECM) (structure, stiffness, immobi-
lized and released factors), other cells (cell–cell contact,
paracrine and autocrine signals) and physical factors
(stretch, electrical signals). Many studies have concen-
trated on the hypoxic environment of the MSC niche [8].
Since oxygen tension (i.e. O2 levels below 8–9 %) [9] can
lead to cellular damage and apoptosis, hypoxia precondi-
tioning of MSCs and pro-survival gene overexpression
(e.g. Akt gene) can lead to reduction in hypoxia-induced
cell death [10]. Hypoxia stimulation can be attained by
transducing hypoxia-inducible factor (HIF)-1α [11] lenti-
virus vector into the MSCs, which increases proliferation
and differentiation rates of the mesenchymal lineages. Cel-
lular repressor of E1A-stimulated genes (CREG) also plays
a role in activating HIF-1α, but not HIF-1β, by degrading a
key protein that degrades HIF-1α [12]. This in turn modu-
lates the paracrine signalling, resulting in upregulation of
angiogenic factors such as vascular endothelial growth fac-
tor (VEGF) [13, 14], stromal cell-derived factor-1α (SDF-
1α) [14], hepatocyte growth factor (HGF) [15] and IL-6
[10]. CREG also leads to reduction in fibrotic tissue and
cardiomyocyte proliferation [11]. MSCs have also been
studied to release extracellular vesicles under hypoxic
conditions, resulting in neoangiogenesis and enhanced
cardiac functioning [16]. Human tissue kallikrein (TK)
gene [17], trimetazidine (TMZ) [18] and midkine [19],
when transduced or overexpressed in MSCs and trans-
planted into rat hearts, were found to provide more resist-
ance to hypoxia-induced apoptosis, inflammatory damage
and cardiac injury. Overall the MSCS promoted enhanced
neovascularization and cardiac functional recovery. TK-
MSCs have also been shown to exhibit enhanced VEGF
expression and reduced caspase-3 activity [17], while
TMZ preconditioning of MSCs led to increased levels of
the anti-apoptotic protein Bcl-2 [20]. However, TMZ has
been observed to induce adverse drug reactions associated
with Parkinson’s syndrome [21] and thus requires careful
evaluation before being established as a promising thera-
peutic agent. Let7b-transfected MSCs also target the cas-
pase-3 expression for upregulating the pro-survival genes
such as p-ERK, Bcl-2 and p-MEK and result in improved
left ventricular ejection fraction (LVEF) in the rat MI
model [22].
Adult stem cells in regenerative medicine
Adult stem cells
Adult stem cells were thought to have a multipotent
lineage, but recent research has highlighted their pluri-
potent nature, transdifferentiating into various progenies
[23]. The progenies in turn form cells of multipotent
lineages, such as HSCs and MSCs [24]. HSCs are pluri-
potent cells that further differentiate into blood cells of
lymphoid (B, T and NK cells) and myeloid (monocyte,
granulocyte, megakaryocyte and erythrocyte) lineages
[25]. They are therefore mainly involved in haematopoi-
esis and treatment of related diseases. MSCs have shown
promising regenerative abilities in stimulating cardiomyo-
cyte formation, in association with a Notch ligand, Jagged
1 [26]. MSCs along with other pluripotent stem cells have
been said to be an effective tool for angiogenesis, cardiac
regeneration and hence cardiac tissue revitalization [27],
and they have also been established to be more effective
than HSCs for treatment of MI in nude rat model [28].
Cardiac stem cells (CSCs) are multipotent in nature,
and are capable of differentiating into vascular cells and
cardiomyocytes [29]. These can be differentiated from
hMSCs on the basis of their inability to differentiate into
osteocytes and adipocytes [30]. The presence of c-kit
marker is used as an interpretation for cardiac progenitor
cells (CPCs) [31]. The cardiac regenerative capacity of
CSCs was studied against that of MSCs and enhanced
levels of histone acetylation at the promoter regions of the
cardiac specific genes were found to be higher in CSCs
than in MSCs [32]. This observation indicates that CSCs
have a higher potential to differentiate into cardiomyo-
cytes than MSCs and has further been supported by ani-
mal studies showing higher modulatory characteristics of
CSCs, such as reduced scar size and vascular overload [33,
34]. Fetal cardiac MSCs (fC-MSCs) are said to be primi-
tive stem cell types with the ability to differentiate into
osteocytes, adipocytes, neuronal cells and hepatocytic cells
[35]. These cells demonstrate a high degree of plasticity
and have a wide spectrum of therapeutic applications.
Cardiac colony-forming unit fibroblasts (CFU-Fs) are
another population of cells which are pro-epicardium
derived and resemble MSCs. According to a study by Wil-
liams et al. [36], combination of hCSCs and hMSCs
enhance the therapeutic response by producing greater in-
farct size reduction post MI. Yet another study highlighted
the prospect of cardiac CFU-Fs holding higher therapeutic
potential than bone marrow-derived MSCs (BM-MSCs)
for cardiac repair [37]. The formation of CFU-Fs has been
said to be enhanced by treatment of BM-MSCs with 1,25-
dihydroxy vitamin D3 [38]. Adult stem cells tend to
undergo cardiomyogenesis due to stimulation by oxytocin
[39] (Fig. 1c) and paracrine factors released by human
cardiac explants which leads to expression of cardiac-
specific markers and differentiation of the MSCs into
cardiomyocyte-like cells [40]. In a study conducted to
estimate the efficacies of different stem cells, the results
suggested that unrestricted somatic stem cells are more
effective in providing cardiac functionality to the damaged
tissue post MI than the BM-MSCs, even though their
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capacity to repair the damage is moderate [41]. An-
other interesting subfamily of the CSCs is cardiac resi-
dent stem cells (CRSCs) which can be obtained from
adult human atrial appendages. These stem cells when
administered with W8B2 antigen exhibit cardiogenic
differentiation capacity, along with secretion of a var-
iety of angiogenic, inflammatory, chemotaxic and cell
growth and survival cytokines [42].
MSCs: a promising source of cell-based therapy
General characteristics
Mesenchymal cells, being multipotent stem cells, can dif-
ferentiate into several cell types such as mesodermal
lineage cells (adipocyte, osteoblast, chondrocyte) [43] and
myogenic lineage [44]. This feature of the MSC makes it
an alluring therapeutic agent. According to the Tissue
Stem Cell Committee of the International Society of Cel-
lular Therapy [45], the basic criteria to categorize stem cell
as MSC include following three key features:
(a)The cells must be plastic adherent under basic
culture conditions.
(b)The cells should express CD73, CD90 and CD105,
lacking the expression of CD11b, CD19 or CD79α,
CD14, CD34, CD45 and HLA-DR surface molecules.
(c)The cells must be able to differentiate to adipocytes,
chondrocytes and osteoblasts in vitro.
MSCs are said to exhibit immunomodulatory effects by
virtue of their inhibitory effect towards both B-cell and T-
Fig. 1 Mechanisms of action of MSCs for cardiac regeneration. (a) miR-133a downregulates the expression of Apaf-1 and caspase 3 and 9, leading
to attenuated fibrosis. ECs producing growth factors such as VEGF-A help in recruiting the peripheral stem cells, along with coordinating the
differentiation of MSCs into endothelial cells, thereby leading to vascularization. BMP7 expressed by MSCs lead to inhibition of fibrosis on
counteraction of TGF-β secreted by macrophages. 5-azacytidine induces differentiation of MSCs into cardiomyocyte, thereby mitigating cardiac
contractibility. (b) PLGF-induced macrophage polarization from M1 to M2 promotes neovascularization. CardioChimeras are mono-nucleate
fusion of CSCs and MSCs which have exclusive growth kinetics, and have proven to be superior to the parent precursors. (c) MSCs pretreated with
various compounds show cryoprotective effects along with enhanced cardiomyogenesis and improved heart function. bFGF basic fibroblast
growth factor, CSC cardiac stem cell, EC endothelial cell, HGF hepatocyte growth factor, LV left ventricular, MSC mesenchymal stem cell, PLGF
platelet-derived growth factor, TGF tumor growth factor, VCAM vascular cell adhesion molecule, VEGF vascular endothelial growth factor
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cell proliferation [46], along with dendritic and NK cells,
to promote allograft survival. In contrast, some studies
have suggested the immunogenicity of MSCs, leading to
proliferation of T cells towards infused MSCs and rejec-
tion of skin allografts by engendering functional memory
T cells [47]. A very recent study has established the char-
acteristics of human MSCs to be phenotypically and
physiologically similar to human cardiac myofibroblasts.
This study was concluded based on the positive staining
of hMSCs for α-SMA, NMMIIB, ED-A fibronectin, vimen-
tin and sp1D8 (collagen type I), which was similar to that
of cardiac myofibroblasts [48].
Cardiomyogenic potential of MSCs obtained from
different sources
MSCs are present in almost all tissues of the body and are
mainly located in the perivascular alcove [49]. These can
be derived from disparate adult (e.g. peripheral blood,
adipose tissue, bone marrow) and neonatal (umbilical
cord, amnion, cord blood and placenta) tissues [49], based
on their therapeutic application. Although bone marrow
represents the major source of MSCs in the body, it does
not qualify as a viable isolation source of the cells due to
high-grade viral infection and a substantial reduction in
the proliferative capacity of the cells with age [50]. Also,
MSC extraction from bone marrow is an invasive proced-
ure, which causes immense pain to the patients and can
also cause an infection [49]. Thus, MSCs derived from
peripheral blood [51], heart [29], lung [52] and adipose tis-
sue [53] have been explored for their biological properties,
differentiation capacities and surface marker expression.
Also, the cells obtained from neonatal tissues have been
found to have superior biological properties as com-
pared with BM-MSCs due to their ready availability,
use of non-invasive techniques and avoidance of ethical
problems [49]. A study categorized BM-MSCs based on
their surface differentiation antigens and found that
SCA-1+/CD31+/CD45+ subgroups displayed substantial
cardiac improvement capacity, as compared to other
BM-MSC subgroups such as SCA-1+/CD45–/CD31–,
SCA-1+/CD45+/CD31– or SCA-1+/CD45–/CD31+ [54].
Several animal cell lines have also been established to
be used as biological tools for ex-vivo expansion and
MSC differentiation into a definite lineage. One such
MSC cell line was obtained using a porcine model,
which when treated with 5-aza differentiated into cells
containing positive cardiac phenotypic markers such as
connexin-43 (Cx-43) and α-actin [55]. A study using
porcine model demonstrated the use of histological
staining as a feasible method to study the effect of these
MSCs in myocardial regeneration [56]. MSCs obtained
from patients with either coronary artery disease
(CAD) or diabetes mellitus (DM), or both, help ameli-
orate cardiac function on transplantation but diabetes
in a patient reduces the myocardial protection and pro-
liferative capacity in hMSCs, as compared with CAD
[57]. Bcl-2 is family of proteins having a critical role in
regulating anti-apoptotic pathways and cell death inhib-
ition [58]. This feature of higher protective and prolif-
erative capacity has been attributed to the lower
expression of Bcl-2 in CAD + DM patients compared
with the CAD-only group [57].
According to one study [59], the traditional therapy
techniques have been effective in treatment of acute dis-
eases and improving a patient’s lifespan, but they do not
serve to provide a permanent cure, thereby leaving the
patients with protracted disease. On the contrary, car-
diovascular regenerative medicine prevents further dis-
ease advancement by replacing the damaged cells with
cardiac myocytes obtained from stem cells [60]. This is
possible because stem cells are responsible for the gener-
ation and maintenance of terminally differentiated cell
populations in tissues that undergo continuous turnover
[2]. For instance, a study conducted by Brunt et al. in-
vestigated the myogenic differentiation based on age,
where bone marrow MSCs were obtained from cardio-
vascular patients and a protein evaluation was con-
ducted to estimate the β-catenin nuclear translocation in
these patients. The study concluded with a first-time dis-
covery of increased β-catenin bioavailability leading to
myogenic differentiation and the WNT/β-catenin net-
work as a potential target for reinvigoration of MSCs
[61]. Regenerative medicine has explored several options
in order to establish the use of MSCs as an expedient
and more pragmatic technique towards cardiac regener-
ation from the various possible sources of regenerative
tissue.
Bone marrow
Differentiation of scar tissue into cardiomyocytes can be
instigated by transplanting bone marrow cells into the
tissue and thereby restoring the myocardial function
[62]. BM-MSCs have shown promising potential in
cardiac repair due to their powerful proliferative capacity
[63, 64], their ability to reduce the infarct size [65] and
their ability to change the milieu of the damaged cardiac
tissue to upregulate VEGF [66]. These have also been
studied specifically for differentiation of CSCs [67]. For
the first time, Cai et al. [68] demonstrated the use of
these MSCs for the treatment of isopreterenol-induced
myocardial hypertrophy. Another interesting observation
in this study included the significance of inhibition of
VEGF, and not fibroblast growth factor (FGF) or insulin-
like growth factor, which restricted the protective effects
of BM-MSCs on the hypertrophic condition [68]. Having
mentioned this, the combined effect of BM-MSCs along
with basic fibroblast growth factor (bFGF)-binding ECM
has been observed to improve the left ventricular (LV)
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function and enhance myocardial regeneration [69]. One
of the most effective delivery methods for the treatment
has been observed to be via the retrograde infusion of
the two [70]. Mixed treatment of BM-MSCs with endo-
thelial progenitor cells (EPCs) pre-treated with salviano-
lic acid B results in reduced infarct area and enhanced
stem cell proliferation [71]. BM-MSCs can be tracked by
labelling them with superparamagnetic iron oxide
(SPIO) nanoparticles in any MI rat [72] or swine model
[73] and locating the shortened T2 value on the MRI
scan. Similarly, quantum dots have been recently identi-
fied as another medium to label and track the cells, both
in vitro and in vivo [74]. Emmert et al. [75] aligned a
series of methods of cell tracking and imaging, including
micron-sized iron-oxide labelling (MPIO), MRI, micro-CT
flow cytometry and PCR followed by immunohistochems-
try, in intra-uterine and intramyocardial (i.m.) BM-MSC
transplantation pre-immune sheep models. The multipo-
tency of these cells has been confirmed by a study based on
human MSCs, which led to their differentiation into adipo-
cytes, chondrocytes and osteoblasts [48]. Despite the simi-
larity of these cells with cardiac myofibroblasts, they
remain different due to their proliferative and differenti-
ation properties, which are characteristic of MSCs. The
repair coordinated by BM-MSCs is mainly mediated by
causing relief from heart failure symptoms, and improving
blood flow to the myocytes [76]. Also, bone marrow was
the first source identified for MSCs, but several alternatives
are being explored due to the invasive and painful extrac-
tion process.
BM-MSCs have been studied to transdifferentiate into
cardiomyocytes, which involves a negative regulation by
histone deacetylase 1 (HDAC1) [77]. HDAC1 when
knocked down leads to directed differentiation of the
MSCs into cardiac cells. Multipotent BM-MSCs when
reprogrammed into pluripotent cells result in MSC-
derived induced pluripotent stem cells (MiPS), which
express cardiac-specific transcription factors and form
spontaneously beating cardiac progenitors [78]. These
MiPS-derived progenitors engender infarcted heart and
lead to improvement in global heart function. Bone mar-
row MSC/silk fibroin/hyaluronic acid (BMSC/SH) was
implanted into myocardial infarcted rat hearts, where
the condition was obtained by cryo-injury technique
[79]. In comparison with the control and the other
experimental models, BMSC-SH proved to improve the
thickness of the LV wall, reduce apoptosis, promote neo-
vascularization and stimulate several paracrine factors
(e.g. VEGF), thereby compiling the advantages of the
bioactive SH patches and stem cell therapy. In another
study, the BM-MSCs were transplanted with induced
(iBM-MSC) and uninduced (uBM-MSC) BM-MSCs in
MI-induced rat hearts. As per the results obtained, the
iBM-MSC-treated hearts showed improved fractional
shortening as compared with any of the other models.
Thus, iBM-MSC implantation has been considered as
another potential therapeutic strategy for post-infarcted
heart failure [80].
A combined therapy of BM-MSCs with Tanshinone
IIA (Tan IIA) increased the migratory rate of the cells to
the ischaemic region by promoting SDF-1α expression in
the area, which was suppressed by AMD3100 (a CXC
chemokine receptor 4 blocker (CXCR4)) [81]. This find-
ing indicated the role of SDF1/CXCR4 in BM-MSC mi-
gration. SDF-1 recruits the MSCs from bone marrow
through a CXCR4-dependent mechanism [82] and when
transfected into MSCs results in improved viability of
the cells in infarcted hearts, thereby preserving the con-
tractile function along with improving the paracrine
action of the cells [83]. Similarly, TG-0054, a CXCR4
antagonist, was studied in debilitating MI and cardiac
dysfunction after 12 weeks of the treatment. This func-
tional improvement is attributed to the ability of TG-
0054 to mobilize the CD271-MSCs and reduce both
plasma and myocardial cytokine levels [84]. BM-MSCs
overexpressing myocardin-related transcription factor-A
(MRTF-A) prevent primary cardiomyocyte apoptosis
caused by H2O2, and thus help in reversing the cardiac
damage after MI [85]. Similarly, overexpression of CREG
in intramyocardially implanted BM-MSCs resulted in
increased angiogenesis and reduced apoptosis and fibro-
sis [12]. Also, BM-MSCs treated with 5-aza along with
exposure to 2G-hypergravity, when transplanted into a
rat MI model, showed positive cardiac markers such as
Nkx2.5, Mef-2 and GATA-4 indicating cardiac differenti-
ation and functional recovery [86]. When GATA-4 and
Nkx2.5 are transfected into BM-MSCs which are then
co-cultured in the myocardial environment, the differen-
tiation capacity of the cells increases along with the
reparative capacity [87]. Another study compared rat
BM-MSCs transfused with 5-aza to those exposed to
electrical stimulation [88]. The results obtained showed
higher levels of Cx-43 and Mef-2c in the second group
as compared with the first. This instigated the idea of
electrically-stimulated MSC differentiation into cardio-
myocytes. Similar results were obtained when a recom-
binant cocktail consisting of IL-6, FGF-2, α-thrombin,
BMP-4, TGF-β1 [89], retinoic acid, activin-A and
insulin-like growth factor was transduced into hMSCs in
order to guide cardiopoiesis [90]. Bone marrow mono-
nuclear cells (BM-MNC) are an attractive source of
MSCs [91] due to the ease of extraction of the cells.
Comparing both of these bone-marrow-derived popula-
tions, MSCs result in higher vascularization, smaller
infarct size [92] and improved LVEF [93] with respect to
mononuclear cells [94]. BM-MSCs have been shown to
degrade functionally and quantitatively with increase in
age of patients undergoing successful reperfusion
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treatment, and hence this aspect of the MSCs needs to
be explored further [95]. Prostaglandin E1 protects BM-
MSCs against serum-deprived induced apoptosis by
decreasing Bax and caspase-3 expression levels and
increasing Bcl-2 expression [96]. In one study, bone
marrow cells derived from heart failure patients were
shown to express higher levels of remodelling enzymes
and pathways regulating tissue remodelling, scar forma-
tion and maturation. This was attributed the increase in
CD146+/SMA-α myofibroblast frequency [97]. Beyond
this, BM-MSCs have shown to promote c-kit+ CSC dif-
ferentiation via the tumour growth factor beta (TGF-β)
signalling pathway, through paracrine activity [98].
Inflow of endogenous c-kit+ cells is also possible by thy-
mosin β4 (Tβ4) administration, which in turn can lead
to significant increase in survival of the transplanted
cells and the vascular growth [99].
Umbilical cord
The MSCs derived from different compartments of the
umbilical cord such as vein, arteries, Wharton’s jelly,
umbilical cord lining and so forth have been observed to
accumulate in damaged tissues and bolster the repair of
the tissues [100]. The umbilical cord-MSCs (UC-MSCs)
are said to have faster self-renewal capacity than the BM-
MSCs and a lower potential of forming teratomas [101]. A
very first study was performed on an animal model where
the cord lining-derived MSCs combined with a vascular-
ized omental flap ameliorated cardiac dysfunction by myo-
cardial revascularization and attenuated remodelling
[102]. Polycaprolactone nanofibres immobilized with UC-
MSC-seeded fibronectin demonstrated enhanced LVEF
and improved cardiac function [103]. Wharton’s jelly-
derived MSCs (WJ-MSCs), obtained from embryonic epi-
blasts, have been identified to have properties of hESCs
and adult stem cells, thereby serving as an alternative
source for stem cells with significant barriers of immunor-
ejection, tumorigenesis, teratoma formation and so forth
[104, 105]. WJ-MSCs are highly specific for cardiac tissue
due to their natural chemoattractive nature [105] and pro-
duction of pro-angiogenic factors such as HGF, VEGF,
angiopoietin and TGF-β1 [106], inducing recruitment of
CSCs [107]. Overexpression of N-cadherin, a cell surface
gene present in UC-MSCs, leads to upregulation of VEGF,
via the ERK signalling pathway [108]. Intracoronary infu-
sion of WJ-MSCs has also been considered an alternative
to BM-MSCs on the basis of their increased LVEF and
decreased incidence of adverse events [109]. H2O2-pre-
conditioned WJ-MSCs have an enhanced therapeutic
effect possibly due to IL-6 production, which leads to
migration and proliferation of endothelial cells (ECs) and
increased neovascularization [110]. Konstantinou et al.
[111] have for the first time demonstrated the formation
of cardiac polymicrotissue by differentiating hUC-MSCs
using a combination of growth factors suramin and
sphignosine-1-phosphate. This generated the possibility of
using the polymicrotissue as a therapeutic patch over the
infarct cardiac area. Similarly, umbilical-cord-derived exo-
some resulted in improved cardiac function by angiogen-
esis and their protective nature towards the myocardial
tissue [112]. Also, 5-aza-induced hUC-MSCs have been
observed to express GATA-4 and Nkx2.5 genes, and to dif-
ferentiate into myocardial cells [113, 114], better than
myocardial-induced fluids [115].
Cord blood
The haematopoietic stem progenitor cells obtained from
umbilical cord blood have been studied to be very useful
for clinical therapy [116–118]. However the presence of
MSCs in umbilical cord blood is disputable because of
the inability to obtain these cells from the gestation term
cord blood [116]. On the contrary, studies suggest the
presence of MSCs in fetal organs [119], with circulation
in pre-term fetus blood, along with the haematopoietic
precursors [120, 121]. This conflicting result has been
attributed to the use of a different percentage of umbil-
ical cord blood harvests in the two studies [116]. In the
results obtained by Lee et al. [122], it is possible to ex-
tract MSCs from the cord blood that would further dif-
ferentiate into mesodermal lineages. Cardiac muscles,
being of mesodermal origin, can therefore also be ob-
tained from cord blood-derived MSCs. Oxytocin exerts a
promigratory effect on umbilical cord blood-derived
MSCs (UCB-MSCs) [123], and the supplementation of
UCB-MSCs with oxytocin results in lowered cardiac fi-
brosis, macrophage infiltration and restoration of Cx-43
expression, along with a sustained ejection fraction [39].
A study established that co-transplantation of hUCB-
CD34+ and hUC-MSCs leads to reduction in collagen
deposition and improved cardiac function in MI rabbits
[124].
Adipose tissue
The colony frequency of cells obtained from adipose tis-
sue is higher than those of bone marrow [125] and cord
blood, and these adipose tissue-derived MSCs (ASCs)
can differentiate into adipocytes, chondrocytes and oste-
oblasts [125]. Although these cells can differentiate into
vascular ECs leading to angiogenesis, along with demon-
strating a paracrine effect in animal models with MI
[126], cardiomyocyte differentiation is not quite feasible
[127]. Under hypoxic conditions, ASCs secrete large
amounts of VEGF, SDF-1 and HGF, increasing the
migration and proliferation of cardiomyocytes and redu-
cing the apoptosis and infarct size [128]. ASCs can be
isolated from the subcutaneous adipose tissue region or
omental region [129]. Liver X receptor (LXR) is helpful
in improving the retention and survival of the injected
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ASCs post MI, and when combined with ASCs leads to
improvement of the cardiac function [130]. This has
been studied to be possible though the toll-like receptor
(TLR)-4/NF-kB and Keap-1/Nrf-2 pathways [131]. Also,
ASCs secrete various cytokines with different immuno-
modulatory effects which contribute a great deal in
tissue regeneration [132, 133]. ASCs with overexpressed
granulocyte chemotactic protein (GCP)-2 have resulted
in enhanced angiogenic potential and survival properties
[134]. Similar results were obtained for dimethyl
sulfoxide-induced ASCs which differentiated into
cardiomyocyte-like cells, eventually resulting in cardiac
function recovery [135]. These cells have thus attracted
great attention in terms of therapeutic approach towards
skeletal tissue repair [132]. ASCs transplanted with
hydrogel and β-galactose-caged nitric oxide donor
showed improved cardiac function and enhanced cell
survival [136]. ASCs embedded in scaffold containing
platelet-rich fibrin are functionally superior to direct
ASC transplantation, in terms of expression of IL-10,
Bcl-2 and TGF-β [137, 138]. Quite recently, another
very interesting discovery made was in relation to the
human adult epicardial fat surrounding the heart
which served as a reservoir for mesenchymal-like pro-
genitor cells (cardiac ATDPCs) [139]. These cells
show cardiac-like phenotype despite their residence in
an adipocytic environment. Also, increasing the num-
ber of cardiac ATDPCs has been shown to exert great
immunosuppression [139] because of increased T-cell
proliferation.
Skeletal muscle
Muscle-derived stem cells (MDSCs) are not restricted to
myogenic or mesenchymal tissues, and can regenerate
bone and muscle along with cartilage healing [140]. Satel-
lite cells have been considered to be skeletal muscle stem
cells, but they have been identified as myogenic precursors
with a committed differentiation lineage that act as a
reservoir of regenerative cells in case of injury [141]. Stud-
ies provide evidence for the formation of myotubes by
transplantation of the satellite cell-containing myoblast
into a MI model [76]. Thus, the muscle precursor cells
derived from satellite cells can be considered as a viable
option for regeneration of myopathic skeletal muscle
[141]. MSCs obtained from skeletal muscle showed
significant improvement in the LVEF of acute MI rat
models, comparable with that of ASCs, but they did
not transdifferentiate into cardiomyocytes or any vas-
cular cells [142]. MDSCs have been a recent focus of
study and these cells can be harvested either from
orthopaedic reconstruct wastes [143] or from healthy
muscle tissue biopsies [144]. The general delivery ap-
proach used for MDSCs is a tissue engineering strat-
egy such as the use of a scaffold.
Placenta
The study by Vellasamy et al. substantiated the presence
of MSCs in the placenta (p-SC) and suggested them as
feasible regenerative medicine. Stem cells can be derived
from two different parts of the placenta, namely chorionic
villi and chorionic plate [145, 146]. These cells demon-
strate the ability to differentiate into osteocytes and adipo-
cytes, and show typical features of MSCs [146]. Along
with their non-tumorigenic property, these cells have
characteristics of both ESCs and MSCs, thereby exhibiting
the capacity to differentiate into the three germ layers
[147]. The major advantage of using this as a source of
MSCs is that they are available in abundance as medical
waste after delivery. The limitation of using p-SCs is the
occurrence of high chances of impurity, since the placenta
is the common medium of exchange between a mother
and the baby.
Amnion
Amniotic mesenchymal cells (AMCs) are derived from
fetal mesoderm and can be peeled off the chorionic
membrane mechanically by blunt dissection [148]. These
are considered a fitting cell source for cellular cardio-
myoplasty by both integrating and differentiating into
cardiac tissue [149]. An in-vivo study assessing the effect
of AMC transplantation in a damaged myocardial tissue,
in comparison with UCB-MSCs and ASCs, showed com-
parable results with respect to decreased infarct size,
cardiomyocyte-like cell differentiation and improved car-
diac function [150]. Also, these cells serve as potential
curative agents due to their chemotactic characteristic
[151], ample availability, lack of ethical concerns and
low immune response [150]. The cardiomyogenic differ-
entiation capacity of AMC has been shown to improve
by administration of IL-10 or progesterone [148].
Fibroblast
Fibroblasts are mesenchymal precursor cells that express
CD34 and CD45 surface markers [152]. They migrate to
the tissues via blood circulation [153], differentiating into
myofibroblasts (contractile cells involved in secretion of
ECM for tissue remodelling and wound healing) [152].
MSCs have been studied to promote myofibroblast con-
gregation in the infarcted area through TGF-β(1)-Smad2
signalling pathway [154]. An important factor discovered
for myofibroblast differentiation is transient receptor
potential cation channel (TRPC6) activity [155]. This
study was conducted in vitro as well as in vivo in an
experimental mice model (TRPC6 knockout mice). The
knockout mice had debilitated myofibroblast differenti-
ation, resulting in increased ventricular dilation and re-
duced cardiac function [156].
Table 1 summarizes some additional information
about the sources of MSCs based on frequency of
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production and proliferation potential in comparison
with BM-MSCs, along with the techniques of adminis-
tration to the intended location. The frequency of MSCs
in tissues is estimated by assay of the CFU-Fs which
serve as the hallmark of these cells [157]. Apart from the
comparison presented in Table 1, a very interesting study
by Ramkisoensing et al. investigated the differentiation
potential of hMSCs derived from ESCs, fetal umbilical
cord, amniotic membrane, bone marrow, adult adipose
tissue and bone marrow. The results proved hESC-
MSCs and fetal hMSCs to be superior to all the other
MSCs co-cultured with neonatal rat cardiomyocytes, in
terms of expression of most cardiac-specific genes, posi-
tive staining for α-actinin, higher basal levels of Cx-43
and formation of capillary-like structures. Additionally,
hESCs and fetal MSCs, when co-cultured with neonatal
rat cardiac fibroblasts, showed no expression of α-actin
and decreased Cx-43 expression. Also unlike adult
MSCs, the MSCs derived from hESCs and fetal tissue
were found to differentiate into three cardiac lineages,
which highlights the developmental stage of the donor
tissue as a significant factor in differentiation study
[158]. The MSCs derived from rat fetal heart also re-
sulted in upregulation of anti-apoptotic, anti-fibrotic and
cardiogenic growth factors when intravenously injected
in a MI rat model [119]. The human fetal liver-derived
MSCs have also been shown to differentiate into
cardiomyocyte-like cells with a combined treatment of
retinoic acid, dimethyl sulfoxide and 5-aza in high dose
[159]. These cells expressed Nkx2.5, cardiac troponin
I (cTnT), Oct4 and desmin after harvesting them in the
mixture.
Table 1 Comparison between different stem cells
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• Insufficiency in the DNA
repair system caused by
ageing, thereby limiting
the function of HSCs [286]
• Insufficient information
on signalling pathway [21]
• Possibility of gonadal
dysfunction and infertility [287]
• Insufficient information
on which MSC source
to be used for the
therapeutic strategy
concerning a disease [19]
• Route of administration
is uncertain for different
diseases [19]
Ethical concerns • Involves human blastocyst
• Consent for blastocyst/egg
donation is required
None specifically • Need for clinical parity
• Consideration required
for cure of children with
ess severe sickle cell disease [287]
None specifically
ESC embryonic stem cell, HSC hematopoietic stem cell, iPSC induced pluripotent stem cell, MSC mesenchymal stem cell, VEGF vascular endothelial growth factor
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Delivery methods of MSCs into host myocardium
Delivery of MSCs into a damaged myocardium is af-
fected by three key factors: nature of the injury, timing
of the treatment and ability of the cells to implant into
the host myocardium [160]. MSCs can be delivered via
several routes such as intravenous (i.v.) and i.m. injec-
tions. A study concluded improved LV function [161],
improved cardiac function and higher efficiency of cell
engraftment post MI in the case of i.m. injection of
MSCs [162]. Also, the MSCs transplanted intramyocar-
dially have been thought to improve myocardial lymph-
atic system due to their property of integrating into the
lymphatic endothelium [163]. BM-MSCs when adminis-
tered via intracoronary injection have been very effective
in angiogenesis and improvement of cardiac function
[164]. An early study for MSC delivery investigated a
tissue engineering approach where two strategies are
mainly applied: engineering of a stem cell-containing
tissue construct or a beating cardiomyocyte-containing
tissue construct [160]. For instance, to give rise to a
stem cell-populated tissue construct poly(lactic–co-gly-
colic acid) (PLGA) [165] can be used as a scaffold and
BM-MSC-derived cardiomyocyte-like cells can be used
for seeded cells [166], which mimicked the structural
and functional aspects of a myocardium [167, 168]. This
construct was found to substantially stimulate MSC dif-
ferentiation into cardiac tissue. PLGA loaded with SDF-
1α and fabricated with coaxial electrospraying limits the
contact between the protein and organic phase. When
bovine serum albumin is incorporated as a carrier pro-
tein, the chemotactic effect of SDF-1α is enhanced and
the synergistic effect leads to higher growth and prolifer-
ation of the cells [169]. Various biomaterials have been
used for development of scaffold in order for it to be an
ECM analogue of the host tissue. In 2014, high-density
cardiac fibroblast was proposed for the development of
ECM scaffolds from cardiac fibroblasts [170]. When
seeded with hESC-derived MSCs, these scaffolds can be
used as a delivery medium for the stem cells. In the
same year Vashi et al. [171] assessed a commercial peri-
cardial material, CarioCel, which served as a scaffold to
cling onto the seeded stem cells and act as a template
for formation of the new issue. A study on collagen-1
scaffold seeded with autologous MSCs demonstrated re-
verse modelling in rat models of chronic MI [172].
There has been limited study on the number of cells that
remain localized at the site of transplantation. One such
study using a hyaluronan-based scaffold for MSCs
showed that although most of the cells had moved to
the border leaving the scaffold, the treatment did man-
age to alleviate fibrosis in the area along with enhanced
vascularization [173]. Hydrogel is a 3D polymeric net-
work that swells up on exposure to water and can be of
various types like collagen, fibrin, gelatin, alginate and so
forth [174]. BM-MSCs with hydrogel composite have
been studied to improve the cardiac functioning by pre-
venting LV remodelling [175]. Gelatin-coated ECM
dishes have also been determined as a suitable method
for MSC differentiation into beating cardiomyocytes
[176]. Along with preserving the structure of the matrix,
this method also yields greater amounts of collagen and
protein [177]. Decellularized ECMs are also used as bio-
logical scaffolds because of their advantage of being able
to mimic the host ECM properties [178]. Several other
ECM proteins have been identified which further lead to
cardiomyocyte differentiation, protection, proliferation
and angiogenesis [177]. Genipin, a natural cross-linking
agent, has been utilized in various studies to fabricate bio-
compatible and stable hydrogels with increased stiffness
and prolonged degradation. This technique does not harm
the possibility of minimally invasive catheter delivery of
the hydrogel [179]. Thermosensitive hydrogel has proved
to be a novel method for delivering MSCs and is based on
N-acryloxysuccinimide, N-isopropylacrylamide, poly(tri-
methylene carbonate)-hydroxyethyl methacrylate and
acrylic acid [180, 181]. This hydrogel-based delivery re-
sults in higher differentiation efficiency of MSCs than co-
culturing of cardiomyocytes and MSCs or chemical induc-
tion. Similarly, polytetrafluoroethylene (PTFE) and por-
cine small intestinal submucosa (pSIS) have been found to
account for varying cell proliferation capacity of CPCs as
compared with MSCs [182]. Another study determined a
self-assembling polypeptide RAD16-II, which when mixed
with cardiac marker-positive MSCs yielded a stable nano-
fibre scaffold, promoting cardiac regeneration at the site
of tissue damage [183]. Some polymeric scaffolds lack
structural integrity and thus prove to be inefficient in their
delivery capacity. Thus, the use of hMSCs encapsulated in
arginine–glycine–asparagine (RGD)-modified alginate mi-
crospheres helps to restore the LV function and increase
the cell survival after an MI, along with enhanced angio-
genesis [184]. A non-invasive cell delivery system was
explored by Xu et al. where they used ultrasound-
mediated bubble destruction for the delivery of drugs,
genes and stem cells by upregulating SDF-1/CXCR4 [185],
and this could be used as an efficient delivery system
[186]. Lee et al. developed spheroid 3D bullets from
hUCB-MSCs to deliver these stem cells without the use of
any cytokines [187]. The factors that seemed essential dur-
ing the formation of the bullets were Ca2+-dependent
cell–cell interaction and presence of E-cadherin as an ad-
hesion molecule. E-cadherin activation was found to
switch on the ERK/Akt signalling pathway required for the
proliferative and paracrine activity of MSCs [187].
Mechanisms of action of MSCs
In normal conditions of a non-injured heart, the MSCs
are found to exist in low numbers, and on induction of
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MI these cells start proliferating rapidly for participation
in wound healing, by generation of fibroblasts and
myofibroblasts.
Homing of MSCs
The transplantation of MSCs after MI has shown that
the cells infiltrate the injured tissue by trafficking
through the ECM [188] and considerably repairing the
cardiac function [189]. To understand the general mech-
anism of MSC infiltration into the damaged cardiac
tissue, some studies have demonstrated the production
of HGF by apoptotic cardiomyocytes, and not by nec-
rotic cardiomyocytes [190]. The recruitment of MSCs
has been credited to the presence of HGF receptor
MET, which activates a wide range of signalling
pathways, one of which leads to attraction of MSCs
to the apoptotic cell death site [191]. This study
also concluded the involvement of platelets in the mi-
gration of MSCs to the apoptotic cardiac cells
through the interaction of high mobility group box-1
(HMGB1), which is a nuclear protein with TLR-4
expressed on MSCs. On activation of platelet,
HMGB1/TLR-4 downregulate MET on MSCs, thereby
impairing the recruitment of the cells. As a result,
gene-knockout or blocking of TLR-4 on MSCs can
lead to improved infiltration of MSCs to the damaged
tissue, thereby increasing the efficacy of MSC-based
therapy [191].
In case of any damaged myocardium, SDF-1α mediates
the homing of the endogenous MSCs [169]. Although the
chemokine receptor CXCR4 has not been found to be
expressed in large amounts on the MSC surface, about
80–90 % of hMSCs have an intracellular storage of the
receptor [192]. Following overexpression by mRNA
nucleofection, the receptor stimulates Ca2+ signalling
through its ligand SDF-1α [193]. SDF-1 functions as a
CD34+ progenitor cell-recruiting agent at the site of dam-
age in an organ [194]. However in conditions such as
dilated cardiomyopathy (DCM), monocyte-chemotactic
protein-1 (MCP-1) has been established as a homing fac-
tor of MSCs because of the presence of chemokine recep-
tor type 2 (CCR2), a MCP-1 receptor, on the cell surface
[195]. Having said this, the further alignment of these
migrated MSCs has been established and therefore add-
itional study is required to determine whether the MSCs
cause transdifferentiation, have a paracrine effect or them-
selves differentiate into cardiomyocytes [195]. There
have been several in-vitro and in-vivo studies to
understand the mechanism of MSC recruitment to
the site of the damaged tissue for the reparative
process to occur, along with its protective characteris-
tic. MSCs either differentiate into beating cardiomyo-
cytes [196], transdifferentiate or induce a paracrine
effect for the regenerative process to occur.
Structural organization for cardiomyogenesis
Cardiac actin is the main component of thin filaments of
cardiac myofibrils and sarcomere. The contraction of
cardiac muscle is mediated by sarcomere [197] and
troponin is an essential protein required for the cardiac
muscle contractility [198] as demonstrated by a study on
familial hypertrophic cardiomyopathy [199]. Beta myosin
is predominantly expressed in the normal human ven-
tricle [200]. In 2011, Wei et al. [201] conducted a study
to investigate the biological characteristics of the sub-
population of MSCs that served as the therapeutic agent
in heart injury and established these cells to be CPCs,
due to expression of cardiac-specific markers α-actin
and cTnT on them. The studies which used 5-aza to
convert MSCs to cardiomyocytes [202], whether BM-
MSCs [203] or UCB-MSCs [204], have shown the ex-
pression of all of the genes in the differentiated cardio-
myocytes, such as desmin, β-myosin heavy chain,
Nkx2.5 and cTnT A [204]. Such studies support the
hypothesis that 5-aza can be useful in the reparative
process of heart ventricle as well as in the amelior-
ation of heart muscle contractility [205] (Fig. 1a).
From earlier studies, cTnT [206] and tropomyosin
[207] have been shown to play a role in Ca2+ regula-
tion during contraction. Results obtained by Asumda
and Chase [208] also anticipate the presence of actin
in BM-MSCs, in addition to the other cardiac iso-
forms of troponin such as troponin I (cTnI), cTnT,
troponin C (cTnC) and that of tropomyosin (cTm)
which appear in the early stages of cardiomyogenic
differentiation.
Paracrine effect
MSCs insulate the cardiac tissue from any kind of damage
by reprogramming the molecular wiring of the cardiac
myocytes, thereby protecting them from any hazardous
compound. For instance, Rogers et al. [209] studied the
therapeutic aspect of hMSCs by co-culturing them with
injured myocytes from a neonatal mouse. The mouse
myocytes were subjected to stress by incubating them
with either toxin cytokine, IL-1β, or with endotoxin, lipo-
polysaccharide (LPS). These two compounds act as pro-
inflammatory cytokines [210]. The hMSCs blocked the
activation of cardiac transcription factor NF-kB, which is
dependent on LPS, IL-1β [209] and IL-6 [211, 212],
thereby inhibiting the adverse effect and rendering protec-
tion to the neonatal mouse myocytes. Co-treatment of
MSCs with various inflammatory factors such as TNF-α
and IL-1β leads to the upregulation of vascular cell adhe-
sion molecule-1 (VCAM-1) [213]. With the increase in
cell adhesion ability, cardiac function was also enhanced.
Several attempts have been made to protect the myocar-
dium against ischaemia through preconditioning, which
has further led to an increase in the levels of TNF-α,VEGF
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and IL-8, along with migration and recruitment of MSCs
to the injured tissue [214].
In normal conditions, the cardiac fibroblasts regulate
the ECM by two mechanisms: synthesis and degradation
of the matrix molecules [215]. The matrix-degrading
enzymes are matrix metalloproteinases (MMPs) which
help the infiltrated myofibroblasts in sequential degrading
of the matrix, followed by ECM synthesis. According to
Wang et al. [216], MSCs affect MMP expression via the
ERK 1/2 signalling pathway, where erythropoietin may act
as a paracrine factor. When MSCs of an old human, trans-
fected with tissue inhibitor of MMP-3 (TIMP3) and VEGF,
was transplanted into a rat model of MI, they showed a
similar degree of angiogenic capacity to that demonstrated
by young MSCs [217]. However, when young MSCs were
injected into aged rat recipients, the results showed a sig-
nificant decrease in scar deposition. This study thus
opened up the possibility of allotransplantation of MSCs
from young donors to older patients suffering from MI
[218]. Neuropeptide Y (NPY) is a neurotransmitter present
in the human central and peripheral nervous system
which helps to regulate the endocrine and autonomic
functions. It has been shown to promote angiogenesis
with similar efficacy as fetal basic fibroblast growth factor
(fbFGF) and VEGF [219]. NPY-induced differentiation of
BM-MSCs into cardiomyocytes leads to improved angio-
genesis and cardiac function along with reduced fibrosis
via upregulation of FGF-2, cycline A2 and eukaryotic initi-
ation factor (EIF)-4E genes [220]. Glycogen synthase kin-
ase (GSK)-3β, when overexpressed in MSCs and injected
into a coronary ligated heart, resulted in improved mortal-
ity, reduced infarct size, LV remodelling and a higher car-
diomyocyte differentiation rate [221]. GSK-3β-MSCs also
upregulated the paracrine factor VEGF-A, which led to in-
creased capillary density and survival of MSCs in the tis-
sue [221]. Similarly, genetically engineered MSCs with
enhanced prostaglandin I synthase (PGIS) gene expression
have been shown to improve cardiac function by reducing
apoptosis and limiting the cardiac remodelling and
increasing the VEGF-A levels, as found in a GSK-3β study
[222]. Injection of MSCs results in activation of the JAK/
signal transducer and activator of transcription 3
(STAT3) signalling pathway which has a role in the up-
regulation of growth factors in both diseased hearts and
skeletal muscles [223]. This became evident from a
study where BM-MSCs improved ventricular function
in cardiomyopathic hamsters [224, 225]. The STAT3
pathway increases the caspase-4 level in the trans-
planted MSCs, and improves the post-ischaemic func-
tion by reducing pro-inflammatory and pro-apoptotic
signalling in the tissue [226].
Macrophages have been another target of study to initi-
ate the neovascularization along with MSCs [227]. Earlier
studies have established that increased levels of VEGF,
produced by STAT3, are the driving force behind angio-
genesis in order to alleviate conditions like DCM [221,
228] and ischaemic reperfusion injury [229]. Additionally,
myocardial mRNA expressions of AT1, TGF-β1 and
CYP11B2 have been found to be lower in a doxorubicin-
induced DCM-MSC group as compared with placebo or
blank groups, where doxorubicin is administered by intra-
peritoneal injection in the rat model [230]. Additionally,
the doxorubicin-induced injury is also possible to mitigate
through BM-MSC or ASC injection [231]. The VEGF
expression is also induced by a combined therapy of gran-
ulocyte growth factor (G-CSF) and BM-MSCs, carrying
HGF for angiogenesis in MI rat models [232]. However,
recent studies have emphasized secretion of platelet-
derived growth factor (PLGF) factor by MSCs to promote
neovascularization [233]. Hence, PLGF was used to check
the proliferation or apoptosis of macrophages. Although
no change was observed, however, a dose-dependent
polarization of M1 macrophage to M2 macrophage was
found to take place which released PLGF 50 times more
than M1. This study suggested that PLGF, not VEGF
secreted by MSCs, stimulates the polarization of macro-
phages which further secrete PLGF to promote neovascu-
larization and enhance cardiac muscle repair [234]
(Fig. 1b). Also, PLGF has been shown to directly stimulate
neovascularization and hence help in cardiac repair [233].
Previous studies have underlined a significant inter-
action between TGF-β1 and bone morphogenetic protein
BMP7 in the epithelial-to-mesenchymal transition for
fibrosis [235, 236] (Fig. 1a). Macrophages express high
TGF-β1 [237] and MSCs express a high level of BMP7
[238] which have a contradictory fibrogenic effect of the
TGF-β secreted by macrophages. Another study showed
improved functional recovery of the ischaemic cardiac
tissue when the MSCs were co-treated with TGF-β1 and
IL-1β, due to an increased VEGF level [239].
Surgical treatment methods are mainly employed only
after a patient suffers MI. This was studied in mammals
for the first time based on a study of neonatal mice
undergoing a 10-min surgery to induce MI [240]. This
procedure leads to vascular injury [241] following which
ECs synthesize cytokines, chemokines and growth fac-
tors such as VEGF-A [242], all of which play a protective
role and stimulate the ECs along with recruitment of
peripheral stem cells [242, 243]. VEGF-A also coordi-
nates the differentiation of MSCs into ECs in vitro [243,
244] (Fig. 1a) and factors such as IL-6 and TNF-α inhibit
VEGF-A-induced differentiation of MSCs into ECs and
subsequent capillary tube formation [245]. However, this
fact has been negated in a study by Mohri et al. [246],
where the authors claimed activation of the JAK/STAT
pathway in CSCs by IL-6 cytokines, which in turn leads
to vasculogenesis of vascular endothelial precursor cells.
Combined treatment of angiotensin II (AngII) and
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VEGF-A effectively increases the marker expression of
ECs despite the presence of IL-6 and TNF-α.
Pre-treatment and conditioning of MSCs
MSCs induced with ischaemic cardiac conditioned
media showed positive reaction for GATA-4, Nkx 2.5
and MLC-2a, suggesting cardiomyogenic differentiation
of MSCs, as compared with the negligible effect by a
non-ischaemic environment exerted on the MSCs [247].
Cardiomyogenic media-primed MSCs enhanced expres-
sions of sarcomeric α-actinin and Cx-43, establishing
themselves as better therapeutic agents than direct MSC
transplantation [248].
Diazoxide is an ATP-sensitive potassium channel regu-
lator present in the mitochondria and plays a role in sup-
pressing apoptosis and promoting cell survival. Selected
MSCs preconditioned with diazoxide resulted in an
improved cell survival rate by upregulating the expression
of bFGF and HGF and protecting the cells from oxidative
stress injury [249].
One of the earlier studies established MSCs pre-treated
with Ang receptor blockers (ARB) as an agent involved in
improvement of cardiac function and also as a potential
CSC source for cardiomyogenesis [250]. In a more recent
study, it was demonstrated that Ang II, through an angio-
tensin II type-2 receptor (AT2R)-dependent mechanism,
promoted the differentiation of MSCs into functional ECs
[251] and upregulated the expression of Cx-43 for gap
junction formation [252] (Fig. 1c). Hence AT2R agonists
and inflammatory compounds are considered key candi-
dates for angiogenesis or vessel repair. G9a is a mamma-
lian histone methyltransferase which acts as a
transcriptional repressor [253]. Thus, use of BIX01294,
which is a G9a HMT inhibitor, induced the expression of
cardiac transcription factors such as GATA-4, Nkx2.5 and
myocardin on BM-MSCs when the cells were exposed to
cardiogenic stimulating factor WNT11 [254]. Islet-1 is
considered another cardiac cell marker [255], and thus
progenitors with Islet-1 can differentiate into various car-
diac lineages. C3H10T1/2 MSCs were used for the study of
cells that differentiated into cardiomyocyte-like cells via
histone acetylation [256]. These cardiomyocyte-like cells
when present in the proximity of myofibres expressing col-
lagen V show escalated integration and recovery of the
infracted myocardium [257].
Effects of modification in MSCs
Heme oxygenase-1 (HO-1) when transduced into MSCs
using an adenoviral vector has been shown to induce
angiogenic effects [258], with enhanced anti-oxidative and
anti-apoptotic capabilities [259], leading to improvement
in cardiac function post MI. Human receptor activity-
modifying protein 1 (hRAMP1) gene when overexpressed
in MSCs using the same vector [260] and tagged with
enhance green fluorescent protein (EGFP) resulted in
smaller infarct size and enhanced cardiac function [261]
by decreasing the TNF-α level, inhibiting NF-kB expression
and enhancing the IL-10 level [260]. hRAMP1-express-
ing MSCs are otherwise also noted to inhibit the vascu-
lar smooth muscle cell proliferation [262]. CXCR4-
overexpressed hypoxic MSCs were also shown to enhance
neovascularization, enhance EC differentiation, reduce
infarct size and restore cardiac function [263]. MSCs
transduced with lentiviral CXCR4 lead to downregulation
of the caspase 3 pathways and upregulation of pAkt and
IGF-1α levels [264].
An animal study used integrin-linked kinase (ILK)-
transfected MSCs to investigate the effect on collagen
synthesis and cardiac fibroblast proliferation. The study
demonstrated inhibition of cardiac fibroblast prolifera-
tion and a few other factors, thereby leading to a
decrease in infarct size and a reduction in fibrosis in
these animals [265] along with increased cardiomyocyte
proliferation [266]. Also, MSC transplantation in in-
farcted area has been shown to enhance the synthesis of
collagen and this could be the mechanism behind atten-
uated ventricular remodelling post transplantation [267].
MSCs are valued for their paracrine effects in reducing
inflammation [188] and promoting growth of the
surrounding cells [268]. MSC injection promotes the
recruitment of CPCs and helps in the improvement of
myocardium [67]. Studies were performed to check the
efficiency of dual cell transplantation on cardiac repair.
These cells were fused to form CardioChimeras (CCs)
which proved to be more efficient than single cell deliv-
ery. CPC phenotype expression dominates CCs and
mediates the cardiomyogenic factors [269]. These cells
also demonstrated the same phenotypic properties of
commitment and high paracrine effect as those of MSCs
along with increased basal expression of cardiomyogenic
factors [269]. To check the effects of CCs and their par-
ental cells, neonatal rat cardiac myocytes were incubated
with them. Addition of CCs increased the expression of
stromal-derived factor, a cardioprotective agent, and also
acted as a ligand to CXCR4+ stem cells [270]. The study
also showed an increase in capillary density in the area
incubated with the CCs (Fig. 1b). Furthermore, the ejec-
tion fraction (fraction of blood being pumped out of the
heart per heartbeat) and the anterior wall thickness of
the heart also showed an improvement [269].
MicroRNA regulation in modified MSCs
Researchers have been investigating several other tech-
niques to accelerate cardiac regeneration, keeping in
mind the feasibility of the process. microRNAs (miRs)
are approximately 22-nucleotide RNAs [271], found
endogenously and involved in post-transcriptional regu-
lation of gene expression. Some of these miRNAs are
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said to be cell specific or tissue specific, helping to
fathom the underlying pathophysiological condition
[272]. miR-133a is muscle specific and is proposed as a
novel therapeutic target in cardiovascular disease [273].
Patients suffering from MI have been shown to have
lower levels of miR-133a [274, 275]. miR-133a is known
to play an important role in terminating embryonic car-
diomyocyte proliferation [276], attenuating fibrosis [277]
and promoting cardiac remodelling [278]. To assess its
role in survival of MSCs, miR-133a was made to express
in these cells. Researchers found that improvement in
MSC survival was due to the attenuation of expression
of Apaf-1 and caspase 9 and 3 (Fig. 1a). In contrast,
depleting or blocking of miR-133a by its antagonist
resulted in upregulation of these proteins [279]. Another
significant study illustrated the overexpression of miR-16
in cardiac-niche-induced hMSCs, when co-cultured with
rat ventricular myocytes [280]. miR-16 was found to in-
hibit cell proliferation, modulate the cell cycle, promote
cell apoptosis and abolish tumorigenicity both in vitro and
in vivo [281]. The induced cardiac niche led to dysregula-
tion of the miRNA and increased G1 phase arrest in
hMSCs, leading to their differentiation into myogenic
phenotypes in the cardiac niche [280]. Similarly, miR-
499 is an embedded miRNA present within a
ventricular-specific myosin heavy chain gene [282].
When overexpressed in rat BM-MSCs, miR-499 acti-
vates the WNT/β-catenin signalling pathway, inducing
cardiac differentiation [283]. Another mechanism of
cardiac protection used by miR-499 is calcineurin-
mediated dynamin-related protein-1 (Drp1) activation,
which prevents cardiomyocyte apoptosis [284]. miR-34
acts as a crucial cell death regulator and its deletion or
silencing reduces the age-associated cardiac cell death
[285]. This occurs due to inactivation or knockdown of
the stem cell factor (SCF), which serves as the main
target of miR-34 and thus lead to inhibition of angio-
genesis [286]. miR-23a is also studied to regulate the
caspase 7-induced apoptosis, involving the TNF-α path-
way, along with a reduction in infarct size and improve-
ment of the LV function [287].
Effects of treatment of MSCs on cardiac regeneration
Several compounds such as pioglitazone [288], rosuvastatin
[289], TMZ [18, 21], gingko biloba extract 761 [290] and
hydrogen sulfide [291] have been demonstrated to enhance
the repair of cardiac tissue in MI models. Pioglitazone is
generally used to increase the insulin sensitivity in diabetic
type 2 patients. Oral intake of this drug after BM-MSC
transplantation has been studied to improve cardiac func-
tion. When used in pre-treatment of MSCs, pioglitazone
yielded significantly upgraded cardiac function and was
even put forward as a promising CSC source for cardio-
myogenesis [288] (Fig. 1c). Combined treatment of MSCs
with pioglitazone showed higher levels of peroxisome
proliferator-activated receptor gamma (PPAR-γ), which in
turn led to increased Cx-43 levels [292]. Similarly rosuvas-
tatin, when administered with ASCs, reduced fibrosis
and safeguarded the cardiac function by decreasing
pro-apoptotic proteins (Bim and Bam) and increasing
anti-apoptotic proteins (Bcl-2 and Bcl-xL), thereby inhi-
biting cardiomyocyte apoptosis [289]. Hydrogen sulfide
led to increased levels of phosphorylated Erk1/2, Akt
and GSK-3β, and resulted in an increased survival rate
of the transplanted MSCs, enhanced LV function and
reduced infarct size [291] (Fig. 1c). Similarly, atorva-
statin treatment increased the expression of CXCR4 in
MSCs, leading to enhanced migration of SDF-1 and low
levels of IL-6 and TNF-α [293] (Fig. 1c). The drug also
facilitated MSC survival along with improvement of LV
function and decrease in the infarct size, inflammation,
fibrosis and apoptosis [294]. Salvianolic acid B pre-
treatment of MSCs has been found to be very effective
in a rat model of MI following transplantation [295].
Improved survival of the transplanted MSCs was ob-
served along with increase in angiogenic factors such as
VEGF, bFGF and SCF with concomitant reduction in fi-
brosis and infarcted area [295] (Fig. 1c). Another study
concluded that a combination of angiogenic factor
genes, chemokine and stem cells could increase the
angiogenesis rate and improve cardiac function [296].
MSCs have also been studied to modulate electro-
physiological properties including the excitability and
conduction of cardiomyocytes by two mechanisms. First,
by intercellular coupling through the gap junction for
reduction in instinctive activity of cardiomyocytes; and
second, by increase in the conduction velocity of cardio-
myocyte by paracrine signalling, via upregulation of Cx-
43 [158] and nerve growth factor [297], without any
amendments in the beating frequency [298]. This thera-
peutic action of MSCs has been studied in a swine model,
which resulted in decreased heart rate turbulence, amelio-
rated repolarization time and higher slope of action poten-
tial durations indicating improved cardiac functioning and
reduced risk of ventricular arrhythmias [299]. In addition,
MSCs have also shown to improve the contractile func-
tion and compensate for a 50 % loss of cardiomyocytes
after any cardiac damage by supplementing the engineered
cardiac tissues (ECTs), which serve as a 3D in-vitro model
system to appraise stem cell therapies [300].
Clinical trials using MSCs in cardiac disease performed
between 2010 and 2015 and their shortcomings
There have been about 41 clinical trials (Additional file 1:
Table S1) performed between 2010 and 2015 for the study
of MSCs in relation to cardiac injury and repair. These tri-
als were performed in distinct locations and were mostly
found to have completed phase II, where some of them
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even managed to reach phase III of the study. The trials
could be characterized in several ways based on their
focus of study. Most of the trials focused on the injection
and infusion of MSCs from different sources into the
injured cardiac tissue, via different sites of injection. The
second type of study compared the different kinds of
MSCs (i.e. autologous and allogeneic MSCs) in context of
both ischaemic as well as non-ischaemic cardiomyopathy
in patients. A third type of study was performed in order
to focus the safety and efficacy of these MSCs when im-
planted into patients, as done in a study by Da Silva and
Hare [301] with the focus on the role of BM-MSCs in the
treatment of chronically injured heart.
In these studies, a number of candidate cells such as neo-
natal and fetal cardiomyocytes, ESC-derived myocytes,
skeletal myoblasts, cell types from adult BM and cardiac
precursor cells have been considered. Autologous BM pro-
genitor cells (mononuclear or MSCs) when administered
myocardially resulted in improved regional contractility
of the myocardial scar within 3 months of treatment
[302] (ClinicalTrials.gov NCT01392625). The trial com-
paring the two BM preparations conducted TAC-HFT
[303] and POSEIDON-DCM [304] studies to estimate
the optimal cell type, delivery method, dose, mechan-
ism of action of cell delivery and so forth. MSCs have
been the main focus of these studies due to their para-
crine effect, high regeneration capacity, ability to per-
petuate potency and ability to avoid adverse reactions
to autologous versus allogeneic transplant. A study
conducted in Korea proved MSC therapy to be safe and
quite efficient in terms of LVEF improvement for the
treatment of acute MI [305] (ClinicalTrials.gov
NCT01392105). A similar study comparing the two
types of bone marrow transplants for patients with LV
dysfunction due to ischaemic cardiomyopathy showed
low alloimmune reactions in allogeneic MSCs and im-
proved functional as well as structural measures when
both were administered together [306] (ClinicalTrials.-
gov NCT01087996). Another study conducted on nine
acute MI patients, following a 5-year follow-up plan to
check the feasibility and safety of i.m. infection, gave a
positive outcomes on MSC expansion and safety of the
method and justified the possibility of placebo-
controlled trials for i.m. MSC injections [307]. A similar
study was conducted for i.v. allogeneic BM-MSCs in
MI patients which proved to be equally efficient in im-
proving the ejection fraction and the LV volumes [308]
(Clinicaltrials.gov NCT00114452). These clinical trials
have concluded the safety and feasibility of BM-MSCs,
but after MI the functional recovery of the cardiac cells
remains ambiguous [309]. A similar study conducted to
investigate the safety and efficacy of WJ-MSCs adminis-
tered via an intracoronary route demonstrated no trig-
ger in troponin concentration as observed with BM-
MSCs, indicating no coronary artery occlusion after the
treatment [109] (ClinicalTrials.gov NCT01291329). An-
other very interesting study was conducted to observe
the combined effects of stem cell implantation and
mechanical circulatory support which resulted in syner-
gistic symptomatic improvement in LV functioning
[310].
Although only a few of the 41 trials have been com-
pleted and the status of some remains unknown, these
trials have established various results which help bolster
the upcoming clinical trials and research. On evaluating
these trials, a definite trend of limitations is evident
which probably played a crucial role in undermining
some of the studies. Firstly, the number of patients in
some of the trials was extremely lower, which could have
compromised the efficacy of the study. Thus, further
large-scale randomized trials are required to establish
successful results. Secondly, the number of patients
excluded in some studies was extremely high because of
several reasons such as poor image quality after
randomization. This leads to generation of unreliable and
non-interpretable data. Thirdly, there is also a possibility
of ignoring inter-observer and intra-observer variability in
evaluating the obtained data at different intervals either
due to manual error or due to unavailability of required
tools such as contrast-enhanced magnetic resonance im-
aging (CE-MRI). Hence, Lee et al. [305] suggested the use
of SPECT to minimize the inter-observer error during
data analysis (ClinicalTrials.gov NCT01392105). Some tri-
als lacked use of diverse assessment tools such as exercise
tolerance, 6-min walking distance test, pulmonary func-
tion test and so forth. This could have restricted the pos-
sible varied outcomes of the trials. Another technical
limitation of the trials using autologous MSCs is the in-
ability to use them immediately since they take at least
3 weeks [311] to harvest and culture to reach an effective
confluence, thereby limiting the efficiency of stem cell
therapy in an acute setting. The randomized clinical trials
concerning these cells need to define the period of treat-
ment. Some experimental limitations include lack of pla-
cebo comparison groups for the study [302], which then
makes the study prone to observational bias (Clinical-
Trials.gov NCT01392625). Some trials evaluated only the
functional aspect of the stem cell therapy, whereas others
focused only on the safety and efficacy of the study, keep-
ing the other factors constant. We anticipate more reliable
outcomes if important criteria such as donor source, cell
type, delivery method, dosage, cohort size and optimal
time of treatment are taken into consideration.
Challenges faced in stem cell therapy
The main challenges faced in the use of stem cells, includ-
ing CSCs, for cardiovascular repair revolve around isola-
tion of adequate stem cells, ex-vivo expansion frequency,
Singh et al. Stem Cell Research & Therapy  (2016) 7:82 Page 14 of 25
appropriate delivery strategy and adequate differentiation
and functional improvement in vivo [27]. In order to over-
come the afore-mentioned challenges, MSCs have proved
to be extremely efficient. Isolation of MSCs is compara-
tively easier; for example, the bone marrow cells can be
extracted from the peripheral blood or the bone marrow
itself [27]. In order to meet the increasing demand of
MSCs, a microcarrier-based stirred culture system tech-
nique has been evolved for the efficient ex-vivo expansion
of the stem cells, for different sources of MSCs using the
various kinds of microcarriers [312]. Mesenchymal cells
have thus attracted immense attention due to their thera-
peutic characteristics and lack of both ethical concerns
and teratogenic properties [313].
Cell therapy precautions
Stem cell therapy has been used for the treatment of can-
cer, repair of damaged tissue and various degenerative
diseases. The potential of such therapies was recognized
long ago, leading to further developments in the field of
stem-cell-based therapeutics. The success of these therap-
ies depends on several factors such as the type of stem cell
being used, its proliferative capacity and differentiation
status, the route and site of administration, survival cap-
ability of the engrafted cells and so forth. On compiling
these factors, a risk profile is generated that then evaluates
the potential risks of the technique which can include
tumour formation along with some other unwanted
immune responses. As far as pluripotent cells like ESCs
and induced pluripotent stem cells are concerned, they
have not demonstrated any clinical risks in any of the
trials. Theoretically, the high proliferation rate and unlim-
ited self-renewal capacity of these cells constitute the risk
of tumour formation. On the contrary, multipotent MSCs
have not reported any major health concerns, implying
the safety of MSC therapy. However, some trials have
recounted serious adverse events [314], such as malignant
tumour formation on transplantation of unmodified BM-
MSCs in the peri-infarct area of a mouse model [315].
This calls for further investigation of the mechanisms in-
volving MSCs. For instance, in a study conducted to ob-
serve an infarcted heart region, several calcified or ossified
encapsulated structures were identified after the injection
of MSCs [316]. A study on arrhythmic mechanisms
established the pro-arrhythmic effects of hMSCs in
neonatal rat cardiomyocytes and the pattern of the
MSCs was said to be determinant of the arrhythmic se-
verity of the myocardial tissue [317]. Another study
concluded the possibility of primary cardiac sarcoma
formation from MSCs, which can further develop into
tumours with multi-lineage differentiation [318]. Ac-
cording to a study conducted by Huang et al. [319],
allogeneic MSC transplantation in the myocardium
exhibited a biphasic immune response of these cells,
resulting in a shift from an immune-privileged state to
an immunogenic phenotype after differentiation leading
to characteristics such as fractional shortening and pro-
gressive ventricular dysfunction. Also, the recent inves-
tigation on electrically stimulated cardiomyocyte-like
cell differentiation needs to be explored in depth [88].
Thus, evaluation of these processes tops the list of
upcoming research on MSCs. Another important con-
sideration in cell therapy is the number of passages
studied in any experiment. For instance, a study based
on commercially available murine MSCs showed alter-
ing expression patterns over a period of time, and this
was further established by comparing the early and late
passages of the model [320].
Conclusion
To evaluate the safety of MSCs in regenerative medicine,
41 clinical trials and more than 120 animal model studies
have been performed since 2010 and these studies have
shown MSCs to have the potential to differentiate into
various mesodermal (e.g. osteoblast, adipocyte and chon-
drocyte) [43] and myeloid lineages [44]. The immuno-
modulatory characteristic of MSCs makes them a worthy
competitor in the field of regenerative therapeutics. How-
ever, many pathways and underlying processes concerning
MSCs still exist that remain unexplored in the field of rep-
arative medicine (Fig. 2). Despite the therapeutic effects of
MSCs, Dayan et al. [321] observed no improvements in
cardiac function in a chronic ischaemic heart failure
model, with no difference in the scar area, fractional
shortening and so forth. A study illustrated induced
and spontaneous transformation of MSCs into sarcomas in
mouse, whereas in humans only induced transformation of
MSCs has been observed [322]. The spontaneous trans-
formation of hMSCs in vitro was found to be caused by
the contamination of the cells by tumour cell lines [323],
and studies have negated the idea of MSC transformation
into tumours, even after long-term culturing of cells [324].
In contrast, in-vivo spontaneous transformation has been
shown to lead to osteosarcoma genesis in patients with
infused BM-MSCs for some other disease [325].
This brings us to the prospective studies in relation to
the therapeutic competency of MSCs. These cells after
transplantation have been shown to demonstrate paracrine
effects which can prove to be of great advantage in future
medical therapies (Fig. 2). Liang et al. [326] evaluated, for
the first time, pigment epithelium-derived factor (PEDF), a
paracrine factor, as a target for modifying and improving
the impaired aged MSCs and thereby enhancing the cellu-
lar profile. The same is possible by overexpressing silent
mating type information regulation 2 homolog 1 (SIRT1)
in aged MSCs to restore pro-angiogenic factors, bFGF and
so forth [327]. The regeneration process can be severely
compromised by the lack of suitable MSC delivery
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methods to the intended site of regeneration and reduced
survival of transplanted MSCs. The delivery methods for
specific MSCs to the specific site of injury have yet not
been established, although several delivery systems such as
engineered tissue constructs and biomaterials have been
explored for the same in order to gain maximum efficiency.
For improving the survival of MSCs, researchers have
been scrutinizing various methods which have proved
beneficial under different conditions. For instance, the use
of alginate-encapsulated MSCs secreting paracrine factors
[328], miRNA [279] and CCs [269] has increased the sur-
vival rate of these cells. Hence, in future, the major areas
of focus should involve figuring out more sustainable/
evolved solutions to the afore-mentioned challenge than
Table 2 Frequency of MSC production, proliferation potential and delivery methods for therapeutic targets in different body organs,
as compared with BM-MSCs
Different sources of MSCs Frequency of productiona Potential of proliferationa Delivery methods for regeneration References
Bone marrow 1 in 3.4 × 104 cells – Intravenously [332]
Umbilical cord matrix Low High Not specified [128, 333]
Amnion High Low Not specified [334]
Placenta High High Not specified [128]
Adipose tissue High High Not specified [55, 105, 128]
Peripheral blood High High Intravenously [128, 335]
Cord blood Low High Intramyocardial, intravenous, intracoronary [103, 336, 337]
aIn comparison with the BM-MSCs
BM-MSC bone marrow-derived mesenchymal stem cell, MSC mesenchymal stem cell
Fig. 2 Challenges in use of MSCs for cardiac regeneration. Tumour formation in MSCs has been considered inconceivable, but there have been
instances of osteosarcoma in patients infused with BM-MSCs for some other disease. Hence, in the context of MSCs in cardiac regeneration, some
pathways and processes might exist that still remain unexplored. Additionally, these pathways comprise MSCs obtained from different sources,
out of which only a few such as BM-MSCs have been used extensively for clinical applications, in spite of evidences of more proliferative capacity
in MSCs obtained from umbilical cord, peripheral blood, etc. This limitation arises due to the lack of an efficient delivery method of MSCs to the
target site. Another challenge that has seemed to come in the way of researchers is the prolonged survival of MSCs post engraftment into the
host myocardium. This challenge has been overcome to a large extent by using miRNAs and CCs, but more sustainable methods need to be
studied further. Studies have gained several advancements in the field of safety and efficacy of the MSC therapy, but success rates in terms of the
functional regeneration of cardiac tissue for the loss of functioning cardiomyocytes after any damage remain mediocre. MSC mesenchymal stem cell
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those under current implementation and more investiga-
tion is required in order to corroborate the efficacy of the
therapies (Fig. 2).
MSCs can also be obtained from different sources in
the body, but the studies in cardiac regeneration are
mainly done using only a few of them. Referring to in-
formation presented in Table 2, the bone marrow has
been established as one of the most promising sources
of MSCs, but there have been studies indicating a
higher MSC production and proliferation capacity in
other parts of the body such as the umbilical cord,
placenta and peripheral blood. Similarly hUC-MSCs
have been found to improve motor function, reduce ab-
normal levels of the concerned enzymes such as lactate
dehydrogenase (LDH), creatine kinase (CK), and so forth,
and increase the muscle strength (ClinicalTrials.gov
NCT01610440). Thus, hUC-MSCs become an important
source of treatment for genetic conditions like Duchenne
muscular dystrophy (DMD). A very important aspect that
plays a crucial role in the treatment of cardiac disorders is
the ability of any treatment strategy to compensate for the
loss of the functioning cardiomyocytes [329]. Thus, one of
the future challenges of cardiovascular therapies is to
strategize the functional regeneration of myocardial
contractility using tissue engineering, cell-based therapy
or reprogramming of scar fibroblasts [330, 331].
Throughout this review we came across compounds
such as pioglitazone [288], rosuvastatin [289] and so
forth that were studied in the initial years of the devel-
opmental era of MSCs but have not received much
attention in recent years, despite the promising results
obtained in cardiac therapy. There thus needs to be
more research carried out on such compounds in order
to not lose out on some extremely propitious thera-
peutic agents. Cell therapy has been adopted as a novel
therapeutic strategy for treatment of cardiac disorders
such as severe heart failure and CAD. Unfortunately,
although these approaches have led to advancements in
the field of safety and efficacy of these cell therapies, the
mediocre success rates in terms of functional improve-
ment serve as a disappointment in the field [3]. Thus we
need to further investigate the sources of MSCs that can
help benefit the treatment of any disorder accordingly
with ‘true’ reparative potential, in order to help focus on
the field of regenerative medicine.
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Additional file 1: Table S1 Clinical trials executed during 2010–2015
which used MSCs to treat heart diseases. (DOCX 36 kb)
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